09:57 AM EST - Field Trip Health Ltd. : Today announced that the U.S. Patent and Trademark Office has granted the Company a patent for claims related to FT-104 (informally known as “Isoprocin Glutarate”), Field Trip’s first novel psychedelic molecule in development. Claims in the patent application titled, “Tryptamine Prodrugs,” grant exclusive rights to Field Trip for the composition of matter, use and manufacturing of a family of hemi-ester compounds of hydroxytryptamines, including FT-104. The patent will provide protection until 2040. Field Trip Health Ltd
shares T.FTRP are trading up $0.02 at $1.59.
